Seven Fleet Capital Management LP → CG Oncology, Inc. CGON

Item 4 of the Schedule 13D is amended to add the following: The Reporting Persons effected an internal restructuring into a master-feeder structure, pursuant to which Seven Fleet Partners LP contributed, for no consideration, all of the 1,515,151 Shares it then held to Seven Fleet Master Fund LP on October 6, 2025 (the "Contribution Date"). Following the Contribution Date, Seven Fleet Partners LP no longer beneficially owns any securities of the Issuer and has ceased to be a reporting person with respect to this Schedule 13D. The restructuring and contribution did not result in any change to Dr. Liu's pecuniary interest in the Shares. This Amendment is being filed pursuant to Rule 13d-2(a) to reflect material changes in the information previously reported, including (i) the restructuring and contribution described above, which changed the identity of the reporting persons and person-level beneficial ownership, and (ii) a correction to the identity of the investment manager disclosed in the initial Schedule 13D. The initial Schedule 13D incorrectly identified "Seven Fleet Advisors" as a reporting person and as the investment manager. The correct investment manager is Seven Fleet Management, and its general partner is Seven Fleet Management GP.